Overexpression of EGFR pathway-related genes in the circulation is highly correlated with EGFR mutations and overexpression in paired cancer tissue from patients with non-small cell lung cancer

Oncology Reports

Volumn 23, Issue 3, 2010, Pages 639-645

  Chen, Chung Chi ^a,b   Chiu, Hua Hsien ^a,b   Yen, Li Chen ^b   Chang, Hui Jen ^a,b   Chang, Ming Sung ^b   Tsai, Jong Rung ^c   Chen, Yi Fang ^d   Lin, Shiu Ru ^a,b  

^a FOOYIN UNIVERSITY   (Taiwan)

^b FOOYIN UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d Gene Target Technology Co Ltd   (Taiwan)

Author keywords

Epidermal growth factor receptor; Non small cell lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; CANCER TISSUE; CIRCULATION; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MOLECULAR SEQUENCE DATA; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; ROC CURVE; SIGNAL TRANSDUCTION;

EID: 77349083210     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000679     Document Type: Article

References (35)

1. Grandis JR and Sok JC: Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 102: 37-46, 2004.
2. Adamson ED: Developmental activities of the epidermal growth factor receptor. Curr Top Dev Biol 24: 1-29, 1990.
3. Zandi R, Larsen AB, Andersen P, Stockhausen MT and Poulsen HS: Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal 19: 2013-2023, 2007.
4. Nicholson RI, Gee JM and Harper ME: EGFR and cancer prognosis. Eur J Cancer 37 (Suppl 4): 9-15, 2001.
5. Gadgeel SM, Ruckdeschel JC, Heath EI, Heilbrun LK, Venkatramanamoorthy R and Wozniak A: Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory nonsmall cell lung cancer (NSCLC). J Thorac Oncol 2: 299-305, 2007.
6. Metro G, Finocchiaro G, Toschi L, et al: Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC). Rev Recent Clin Trials 1: 1-13, 2006.
7. Baselga J: Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact? J Clin Oncol 22: 759-761, 2004.
8. Matar P, Rojo F, Cassia R, et al: Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res 10: 6487-6501, 2004.
9. Dutta PR and Maity A: Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett 254: 165-177, 2007.
10. Dziadziuszko R, Witta SE, Cappuzzo F, et al: Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer. Clin Cancer Res 12: 3078-3084, 2006.
11. Hirsch FR, Varella-Garcia M, McCoy J, et al: Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 23: 6838-6845, 2005.
12. Chen YF, Wang JY, Wu CH, Chen FM, Cheng TL and Lin SR: Detection of circulating cancer cells with K-ras oncogene using membrane array. Cancer Lett 229: 115-122, 2005.
13. Chong IW, Chang MY, Sheu CC, et al: Detection of activated K-ras in non-small cell lung cancer by membrane array: A comparison with direct sequencing. Oncol Rep 18: 17-24, 2007.
14. Chou WC, Huang SF, Yeh KY, et al: Different responses to gefitinib in lung adenocarcinoma coexpressing mutant- and wild-type epidermal growth factor receptor genes. Jpn J Clin Oncol 36: 523-526, 2006.
15. Sharma SV, Bell DW, Settleman J and Haber DA: Epidermal growth factor receptor mutations in lung cancer. Nat Rev 7: 169-181, 2007.
16. Sordella R, Bell DW, Haber DA and Settleman J: Gefitinibsensitizing EGFR mutations in lung cancer activate antiapoptotic pathways. Science 305: 1163-1167, 2004.
17. Pedersen MW, Pedersen N, Ottesen LH and Poulsen HS: Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII. Br J Cancer 93: 915-923, 2005.
18. Arteaga CL and Johnson DH: Tyrosine kinase inhibitors - ZD1839 (Iressa). Curr Opin Oncol 13: 491-498, 2001.
19. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) (corrected). J Clin Oncol 21: 2237-2246, 2003.
20. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290: 2149-2158, 2003.
21. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004.
22. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.
23. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-13311, 2004.
24. Cappuzzo F, Magrini E, Ceresoli GL, et al: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 96: 1133-1141, 2004.
25. Huang SF, Liu HP, Li LH, et al: High frequency of epidermal growth factor receptor mutations with complex patterns in nonsmall cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10: 8195-8203, 2004.
26. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T and Mitsudomi T: Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64: 8919-8923, 2004.
27. Asahina H, Yamazaki K, Kinoshita I, Yokouchi H, Dosaka-Akita H and Nishimura M: Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L. Lung Cancer 54: 419-422, 2006.
28. Kosaka T, Yatabe Y, Endoh H, et al: Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 12: 5764-5769, 2006.
29. Shigematsu H, Lin L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 339-346, 2005.
30. Suzuki M, Shigematsu H, Hiroshima K, et al: Epidermal growth factor receptor expression status in lung cancer correlates with its mutation. Hum Pathol 36: 1127-1134, 2005.
31. Han SW, Kim TY, Hwang PG, et al: Predictive and prognostic impact of epidermal growth factor receptor mutation in nonsmall-cell lung cancer patients treated with gefitinib. J Clin Oncol 23: 2493-2501, 2005.
32. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al: Molecular predictors of outcome with gefitinib in a phase III placebocontrolled study in advanced non-small-cell lung cancer. J Clin Oncol 24: 5034-5042, 2006.
33. Cappuzzo F, Ligorio C, Janne PA, et al: Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: The ONCOBELL Trial. J Clin Oncol 25: 2248-2255, 2007.
34. Hosokawa S, Toyooka S, Fujiwara Y, et al: Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer. Lung Cancer (In press).
35. Cappuzzo F, Hirsch FR, Rossi E, et al: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-smallcell lung cancer. J Natl Cancer Inst 97: 643-655, 2005.